Fluicell AB (ST:FLUI) — Market Cap & Net Worth
Market Cap & Net Worth: Fluicell AB (FLUI)
Fluicell AB (ST:FLUI) has a market capitalization of $4.64 Million (Skr43.13 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #28824 globally and #648 in its home market, demonstrating a -3.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fluicell AB's stock price Skr31.40 by its total outstanding shares 1373703 (1.37 Million). Also see total assets of Fluicell AB for a full breakdown of the balance sheet.
Fluicell AB Market Cap History: 2018 to 2026
Fluicell AB's market capitalization history from 2018 to 2026. Data shows growth from $1.02 Million to $4.64 Million (8.99% CAGR). Also see Fluicell AB (FLUI) cash flow conversion for how efficiently the company converts equity into cash flow.
Fluicell AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fluicell AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Fluicell AB stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.25x
Fluicell AB's market cap is 0.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.02 Million | $1.23 Million | -$14.70 Million | 0.83x | N/A |
| 2019 | $1.29 Million | $2.49 Million | -$18.64 Million | 0.52x | N/A |
| 2020 | $3.02 Million | $4.63 Million | -$18.15 Million | 0.65x | N/A |
| 2021 | $2.97 Million | $2.60 Million | -$21.72 Million | 1.14x | N/A |
| 2022 | $384.36K | $3.25 Million | -$21.49 Million | 0.12x | N/A |
| 2023 | $93.43K | $3.34 Million | -$26.55 Million | 0.03x | N/A |
| 2024 | $6.06K | $1.86 Million | -$15.51 Million | 0.00x | N/A |
| 2025 | $1.48 Million | $6.00 Million | -$8.33 Million | 0.25x | N/A |
Competitor Companies of FLUI by Market Capitalization
Companies near Fluicell AB in the global market cap rankings as of September 19, 2026. Review FLUI tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Fluicell AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Fluicell AB Historical Marketcap From 2018 to 2026
Between 2018 and today, Fluicell AB's market cap moved from $1.02 Million to $ 4.64 Million, with a yearly change of 8.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr4.64 Million | +214.00% |
| 2025 | Skr1.48 Million | +24290.24% |
| 2024 | Skr6.06K | -93.51% |
| 2023 | Skr93.43K | -75.69% |
| 2022 | Skr384.36K | -87.06% |
| 2021 | Skr2.97 Million | -1.47% |
| 2020 | Skr3.02 Million | +133.94% |
| 2019 | Skr1.29 Million | +26.40% |
| 2018 | Skr1.02 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Fluicell AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.64 Million USD |
| MoneyControl | $4.64 Million USD |
| MarketWatch | $4.64 Million USD |
| marketcap.company | $4.64 Million USD |
| Reuters | $4.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fluicell AB
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve sys… Read more